Vanda Pharmaceuticals Inc., of Washington, reported total net product sales of $41.3 million for the third quarter. Sales of Hetlioz (tasimelteon) were $22.3 million, down 1 percent from the second quarter. Sales of Fanapt (iloperidone) were $19.1 million, down 3 percent from the prior quarter. Third-quarter non-GAAP net loss was $1.3 million, or 3 cents per share. The company had $22.5 million in cash and equivalents as of Sept. 30, with another $117.3 million in marketable securities. Shares of Vanda (NASDAQ:VNDA) closed Wednesday at $13.10, down $1.85.